Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $1,747,332.00 in Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 1,078,600 shares of Tevogen Bio stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the completion of the sale, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Tevogen Bio Trading Up 54.0 %

NASDAQ:TVGN opened at $2.48 on Thursday. The stock has a 50 day moving average of $0.63 and a two-hundred day moving average of $0.86. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $21.09.

Analyst Ratings Changes

Separately, Fundamental Research set a $4.20 price objective on shares of Tevogen Bio and gave the company a “buy” rating in a report on Friday, June 28th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio makes up about 3.0% of Portland Global Advisors LLC’s holdings, making the stock its 9th biggest holding. Portland Global Advisors LLC owned about 36.55% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.